Barclays analyst Stephanie Davis maintained a Buy rating on HealthStream (HSTM – Research Report) today and set a price target of $32.00. The company’s shares closed yesterday at $26.41.
According to TipRanks, Davis is an analyst with an average return of -6.9% and a 40.34% success rate. Davis covers the Healthcare sector, focusing on stocks such as Laboratory, Healthequity, and Health Catalyst.
In addition to Barclays, HealthStream also received a Buy from Craig-Hallum’s Matt Hewitt in a report issued yesterday. However, on the same day, JMP Securities maintained a Hold rating on HealthStream (NASDAQ: HSTM).
The company has a one-year high of $29.09 and a one-year low of $20.41. Currently, HealthStream has an average volume of 110.2K.
Based on the recent corporate insider activity of 43 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of HSTM in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
HealthStream (HSTM) Company Description:
HealthStream, Inc. engages in the provision of services to healthcare organizations and other members within the healthcare industry. It operates through the following segments: Workforce Solutions and Provider Solutions. The Workforce Solutions segment offers talent management, training, certification, competency assessment, and performance appraisal services. The Provider Solutions consists of credentialing, privileging, call center, and enrollment products and services. The company was founded by Robert A. Frist, Jr. and Jeffery L. McLaren in 1990 and is headquartered in Nashville, TN.
